Almost all (95%) Medicare drug plans cover Repatha. This includes standalone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Repatha is a brand ...

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha-treated and placebo-treated patients, respectively. The most common ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...

Amgen on Friday revealed its PCSK9 drug Repatha (evolocumab) reduced the risk of major adverse cardiovascular events but had no effect on cardiovascular death, mixed results which could spell ...

Amgen's Repatha (evolocumab) has shown benefit in a long-term study in reducing cardiovascular incidents in patients without a prior history of heart attack or stroke. This comes several weeks after ...

Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only ...

THOUSAND OAKS, Calif., Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha ® (evolocumab) Pushtronex ™ system (on-body infusor with prefilled cartridge), a ...

Credit: Amgen. The Repatha Pushtronix System will be discontinued as of June 30, 2024. Amgen has announced that the Repatha (evolocumab) Pushtronix ® System (single-dose on-body infusor with prefilled ...

Amgen's Repatha was shown to reduce the risk of cardiovascular events, such as cardiovascular death and myocardial infarction, in phase 3 of the FOURIER study. Full results will be presented in March ...

Amgen is cutting the list price of its cholesterol drug Repatha by 60% to $5,850 in an unprecedented move to make the drug available to senior citizens. “We’ve got to make sure those who need [Repatha ...